Bioxyne (ASX:BXN) announced a strategic manufacturing agreement with the Canadian-based industry giant, Aurora Cannabis.
Under the terms of the deal, Bioxyne's wholly owned subsidiary, Breathe Life Sciences, will take the lead in producing pharmaceutical-grade medicinal cannabis products for Aurora.
The partnership serves as a major validation of Bioxyne’s Good Manufacturing Practice certified expertise.
The initial scope of the agreement focuses on the supply of GMP-certified medicinal cannabis oils specifically for the Australian market, with the company confirming that first deliveries have already been successfully completed.
However, the collaboration is set to scale rapidly, with plans already in place to expand production to include GMP-manufactured cannabis vapes.
The products are slated for distribution across premium international markets, including the United Kingdom and Germany, where demand for precision-dosed medicinal formats continues to climb.
CEO Sam Watson noted that the partnership represents a transformative moment for the company, affirming their ability to deliver scalable, high-quality solutions to top-tier industry leaders.
At the time of reporting, Bioxyne's share price was $0.065.